Home › Trials › NCT07310290
Clinical trial Recruiting at 3 sites Observational Ages 18 and up

Using ubrogepant during the migraine prodrome to reduce attack severity

Official title: PHASES: Prodrome in tHe reAl World: aSsESsing Ubrogepant Acute Use

Run by AbbVie · NCT07310290 · Data updated 2026-11-12

This project will try taking oral ubrogepant during the migraine prodrome to see if it reduces attack severity in adults who already take ubrogepant.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment189 (estimated)
SponsorAbbVie
Industry-sponsored
Locations3 sites (Aliso Viejo, California and 2 other locations)
StatusRecruiting
StartedJanuary 27, 2026
Main results expectedMarch 2027
Study endsMarch 2027
Registry record updatedFebruary 10, 2026
Trial IDNCT07310290 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with an ICHD-3 diagnosis of migraine who experience 4–10 migraine days per month and have been prescribed and using ubrogepant for at least 3 months are ideal candidates.

Probably not a fit

Patients not prescribed ubrogepant, using strong CYP3A4 inhibitors, enrolled in other concurrent studies, or who do not meet the 4–10 migraine days per month criterion are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll adults with a clinical diagnosis of migraine who have 4–10 migraine days per month and who have been using prescription ubrogepant for at least 3 months. About 189 participants across roughly 15 US sites will continue their prescribed ubrogepant as part of routine care and record timing and severity of migraine attacks over a follow-up period of up to 13 weeks. The study compares patient-reported attack severity when ubrogepant is taken during the prodrome phase versus usual acute treatment timing using real-world data. No study drug is provided and participants attend regular clinic visits according to their usual care.

Why it matters

Potential benefit: If successful, taking ubrogepant during the prodrome could lessen headache severity and associated symptoms, improving symptom control and reducing the impact of attacks.

How similar studies have gone: Ubrogepant is approved for acute migraine relief, but using it specifically during the prodrome phase has limited evidence from large real-world studies and remains relatively untested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* History of 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1

  --a. Participants with a diagnosis of chronic migraine who report having 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1 due to concomitant preventive treatment are allowed in the study
* Participant is currently prescribed ubrogepant and has been using ubrogepant for at least 3 months for the acute treatment of migraine in adults, according to the US Food and Drug Administration (FDA)-approved indication
* Adult participants with current clinical diagnosis of migraine or chronic migraine according to International Classification of Headache Disorders (ICHD)-3

Exclusion Criteria:

* Currently participating in a concurrent clinical or non-interventional study.
* Concomitant use with a strong Cytochrome P450 3A4 (CYP3A4 ) inhibitor.
* Current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia, status migrainosus or painful cranial neuropathy as defined by ICHD-3

Where it's running

  • Neurology and Pain Specialty Center /ID# 278508
    Aliso Viejo, California, United States     Recruiting
  • Chicago Headache Center & Research Inst /ID# 272345
    Naperville, Illinois, United States     Recruiting
  • Tri City Research Center, LLC /ID# 278800
    Grand Island, Nebraska, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Migraine 167AbbVie 111
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.